<p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL - 獲取免費報告）在週五發佈的報告中，HC Wainwright 將其目標股價從 568.00 美元上調至 620.00 美元，Benzinga 報道。該公司目前對這家生物製藥公司的股票給予 “買入” 評級。HC Wainwright 的目標股價意味着該股票相較於之前收盤價有 11.96% 的潛在上漲空間。</p>
<ul>
<li>MarketBeat 週報 – 09/08 - 09/12</li>
</ul>
<p>其他研究分析師最近也對該公司發佈了研究報告。瑞銀集團在 8 月 12 日的研究報告中重申了對 Madrigal Pharmaceuticals 的 “買入” 評級，並將目標股價上調至 523.00 美元（之前為 458.00 美元）。花旗集團在 11 月 5 日的報告中重申了對 Madrigal Pharmaceuticals 的 “跑贏大盤” 評級。派珀·桑德勒在 10 月 15 日的研究報告中將 Madrigal Pharmaceuticals 的目標股價從 400.00 美元上調至 540.00 美元，並給予該公司 “增持” 評級。B. Riley 在 9 月 29 日的報告中將 Madrigal Pharmaceuticals 的目標股價從 460.00 美元上調至 560.00 美元，並給予該股票 “買入” 評級。最後，Citizens Jmp 在 11 月 5 日的研究報告中將 Madrigal Pharmaceuticals 的目標股價從 485.00 美元上調至 527.00 美元，並給予該公司 “市場跑贏大盤” 評級。十三位股票研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，Madrigal Pharmaceuticals 的共識評級為 “適度買入”，共識目標股價為 553.50 美元。</p>
<p><strong>查看我們最新的 MDGL 研究報告</strong></p>
<h2>Madrigal Pharmaceuticals 股價上漲 2.1%</h2>
<ul>
<li>CoreWeave 和 Madrigal 的內部交易閃現看漲信號</li>
</ul>
<p>Madrigal Pharmaceuticals 的股票在週五交易中上漲了 11.65 美元，達到 553.77 美元。該股票的交易量為 108,002 股，而其平均交易量為 370,878 股。Madrigal Pharmaceuticals 的 1 年最低價為 265.00 美元，1 年最高價為 577.90 美元。該股票的 50 日簡單移動平均價為 454.65 美元，200 日簡單移動平均價為 370.97 美元。該公司的速動比率為 4.78，流動比率為 5.11，債務與股本比率為 0.17。該公司的市值為 125.8 億美元，市盈率為-43.23，貝塔值為-1.04。</p>
<p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL - 獲取免費報告）最後一次公佈季度財報是在 11 月 4 日。該生物製藥公司報告每股收益（EPS）為-5.08 美元，低於市場共識預期的-2.01 美元，差距為-3.07 美元。Madrigal Pharmaceuticals 的股本回報率為-38.38%，淨利潤率為-54.68%。研究分析師平均預計 Madrigal Pharmaceuticals 在當前財政年度的每股收益為-23.47 美元。</p>
<h2>內部買入和賣出</h2>
<ul>
<li>諾和諾德：GLP-1 銷售的新推動力即將到來</li>
</ul>
<p>在其他新聞中，董事 Kenneth Bate 在 11 月 5 日的交易中出售了 16,575 股該股票。該股票的平均售價為 484.30 美元，總價值為 8,027,272.50 美元。出售完成後，該董事直接持有 2,627 股公司股票，價值約為 1,272,256.10 美元。這代表着他們持股比例減少了 86.32%。該交易已在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，董事 Richard S. Levy 在 11 月 13 日的交易中出售了 8,500 股該公司的股票。該股票的平均售價為 520.96 美元，總交易額為 4,428,160.00 美元。出售完成後，該董事在公司持有 21,197 股，價值約為 11,042,789.12 美元。該交易使其持股比例減少了 28.62%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士共出售了 32,354 股公司股票，價值為 15,699,173 美元。內部人士持有公司股票的比例為 21.50%。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者和對沖基金最近對該股票的持倉進行了調整。Envestnet Asset Management Inc.在第一季度將其在 Madrigal Pharmaceuticals 的持股增加了 1.8%。Envestnet Asset Management Inc.目前持有 15,270 股該生物製藥公司的股票，價值為 5,058,000 美元，此前在該期間內又購買了 269 股。安聯資產管理公司在第一季度將其在 Madrigal Pharmaceuticals 的持倉增加了 59.1%。安聯資產管理公司目前持有 1,556 股該生物製藥公司的股票，價值為 515,000 美元，此前在上個季度又收購了 578 股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度購買了 Madrigal Pharmaceuticals 的新股份，價值約為 652,000 美元。Assetmark Inc.在第一季度將其在 Madrigal Pharmaceuticals 的持股增加了 24.0%。Assetmark Inc.目前持有 5,183 股該生物製藥公司的股票，價值為 1,717,000 美元，此前在該期間內又收購了 1,003 股。最後，LPL Financial LLC 在第一季度將其在 Madrigal Pharmaceuticals 的持倉增加了 490.5%。LPL Financial LLC 目前持有 30,822 股該生物製藥公司的股票，價值為 10,209,000 美元，此前在上個季度又購買了 25,602 股。機構投資者持有公司 98.50% 的股票。</p>
<h2>關於 Madrigal Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Madrigal Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發用於治療美國非酒精性脂肪性肝炎（NASH）的治療藥物。其主要產品候選藥物是 resmetirom，一種針對肝臟的甲狀腺激素受體β激動劑，目前正在進行 NASH 的三期臨牀試驗。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非 Madrigal Pharmaceuticals</li>
<li>金融服務股票投資</li>
<li>4 只高風險成長股，價格低於 15 美元，值得關注</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>沃爾瑪股票在穩健的第三季度後大幅上漲——未來增長更強勁</li>
<li>尋找並盈利交易 52 周低點的股票</li>
<li>微軟的 AI 超級工廠可能推動股票反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Madrigal Pharmaceuticals 嗎？</h2>
<p>在考慮 Madrigal Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Madrigal Pharmaceuticals 並不在名單上。</p>
<p>雖然 Madrigal Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Madrigal制藥

<p>HC Wainwright 將 Madrigal Pharmaceuticals 的目標股價從 568 美元上調至 620 美元，維持 “買入” 評級，顯示出 11.96% 的潛在上漲空間。其他分析師也給予了積極評級，普遍目標價為 553.50 美元。Madrigal 的股票上漲 2.1%，報 553.77 美元。該公司報告的季度每股收益為（5.08 美元），未能達到預期。內部交易出現顯著的股票出售，機構投資者調整了他們的持倉。Madrigal 的市值為 125.8 億美元，市盈率為 -43.23</p>

<p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) had its price target lifted by HC Wainwright from $568.00 to $620.00 in a report issued on Friday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 11.96% from the stock's previous close.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL - 獲取免費報告）在週五發佈的報告中，HC Wainwright 將其目標股價從 568.00 美元上調至 620.00 美元，Benzinga 報道。該公司目前對這家生物製藥公司的股票給予 “買入” 評級。HC Wainwright 的目標股價意味着該股票相較於之前收盤價有 11.96% 的潛在上漲空間。</p>
</div><ul>
<li>MarketBeat Week in Review – 09/08 - 09/12</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 09/08 - 09/12</li>
</ul>
</div><p>Other research analysts also recently issued research reports about the company. UBS Group restated a &#34;buy&#34; rating and issued a $523.00 target price (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Citigroup reiterated an &#34;outperform&#34; rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 5th. Piper Sandler boosted their price target on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 15th. B. Riley increased their price objective on Madrigal Pharmaceuticals from $460.00 to $560.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, September 29th. Finally, Citizens Jmp raised their price objective on shares of Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a &#34;market outperform&#34; rating in a research report on Wednesday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $553.50.</p>
<div class="lb-trans"><p>其他研究分析師最近也對該公司發佈了研究報告。瑞銀集團在 8 月 12 日的研究報告中重申了對 Madrigal Pharmaceuticals 的 “買入” 評級，並將目標股價上調至 523.00 美元（之前為 458.00 美元）。花旗集團在 11 月 5 日的報告中重申了對 Madrigal Pharmaceuticals 的 “跑贏大盤” 評級。派珀·桑德勒在 10 月 15 日的研究報告中將 Madrigal Pharmaceuticals 的目標股價從 400.00 美元上調至 540.00 美元，並給予該公司 “增持” 評級。B. Riley 在 9 月 29 日的報告中將 Madrigal Pharmaceuticals 的目標股價從 460.00 美元上調至 560.00 美元，並給予該股票 “買入” 評級。最後，Citizens Jmp 在 11 月 5 日的研究報告中將 Madrigal Pharmaceuticals 的目標股價從 485.00 美元上調至 527.00 美元，並給予該公司 “市場跑贏大盤” 評級。十三位股票研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，Madrigal Pharmaceuticals 的共識評級為 “適度買入”，共識目標股價為 553.50 美元。</p>
</div><p><strong>View Our Latest Research Report on MDGL</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MDGL 研究報告</strong></p>
</div><h2>Madrigal Pharmaceuticals Trading Up 2.1%</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 股價上漲 2.1%</h2>
</div><ul>
<li>CoreWeave and Madrigal's Insider Trades Flash Bullish Signals</li>
</ul>
<div class="lb-trans"><ul>
<li>CoreWeave 和 Madrigal 的內部交易閃現看漲信號</li>
</ul>
</div><p>Shares of Madrigal Pharmaceuticals stock traded up $11.65 during trading on Friday, hitting $553.77. The stock had a trading volume of 108,002 shares, compared to its average volume of 370,878. Madrigal Pharmaceuticals has a 1 year low of $265.00 and a 1 year high of $577.90. The stock has a 50 day simple moving average of $454.65 and a 200 day simple moving average of $370.97. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $12.58 billion, a PE ratio of -43.23 and a beta of -1.04.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals 的股票在週五交易中上漲了 11.65 美元，達到 553.77 美元。該股票的交易量為 108,002 股，而其平均交易量為 370,878 股。Madrigal Pharmaceuticals 的 1 年最低價為 265.00 美元，1 年最高價為 577.90 美元。該股票的 50 日簡單移動平均價為 454.65 美元，200 日簡單移動平均價為 370.97 美元。該公司的速動比率為 4.78，流動比率為 5.11，債務與股本比率為 0.17。該公司的市值為 125.8 億美元，市盈率為-43.23，貝塔值為-1.04。</p>
</div><p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. On average, research analysts expect that Madrigal Pharmaceuticals will post -23.47 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL - 獲取免費報告）最後一次公佈季度財報是在 11 月 4 日。該生物製藥公司報告每股收益（EPS）為-5.08 美元，低於市場共識預期的-2.01 美元，差距為-3.07 美元。Madrigal Pharmaceuticals 的股本回報率為-38.38%，淨利潤率為-54.68%。研究分析師平均預計 Madrigal Pharmaceuticals 在當前財政年度的每股收益為-23.47 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買入和賣出</h2>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德：GLP-1 銷售的新推動力即將到來</li>
</ul>
</div><p>In other news, Director Kenneth Bate sold 16,575 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $484.30, for a total value of $8,027,272.50. Following the completion of the sale, the director directly owned 2,627 shares of the company's stock, valued at approximately $1,272,256.10. This represents a 86.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard S. Levy sold 8,500 shares of the firm's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $520.96, for a total transaction of $4,428,160.00. Following the completion of the sale, the director owned 21,197 shares in the company, valued at approximately $11,042,789.12. The trade was a 28.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 32,354 shares of company stock valued at $15,699,173. Insiders own 21.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Kenneth Bate 在 11 月 5 日的交易中出售了 16,575 股該股票。該股票的平均售價為 484.30 美元，總價值為 8,027,272.50 美元。出售完成後，該董事直接持有 2,627 股公司股票，價值約為 1,272,256.10 美元。這代表着他們持股比例減少了 86.32%。該交易已在與證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。此外，董事 Richard S. Levy 在 11 月 13 日的交易中出售了 8,500 股該公司的股票。該股票的平均售價為 520.96 美元，總交易額為 4,428,160.00 美元。出售完成後，該董事在公司持有 21,197 股，價值約為 11,042,789.12 美元。該交易使其持股比例減少了 28.62%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士共出售了 32,354 股公司股票，價值為 15,699,173 美元。內部人士持有公司股票的比例為 21.50%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its holdings in Madrigal Pharmaceuticals by 1.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 15,270 shares of the biopharmaceutical company's stock valued at $5,058,000 after buying an additional 269 shares during the period. Allianz Asset Management GmbH boosted its position in shares of Madrigal Pharmaceuticals by 59.1% during the 1st quarter. Allianz Asset Management GmbH now owns 1,556 shares of the biopharmaceutical company's stock valued at $515,000 after acquiring an additional 578 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Madrigal Pharmaceuticals in the first quarter valued at about $652,000. Assetmark Inc. increased its stake in Madrigal Pharmaceuticals by 24.0% in the first quarter. Assetmark Inc. now owns 5,183 shares of the biopharmaceutical company's stock valued at $1,717,000 after acquiring an additional 1,003 shares during the period. Finally, LPL Financial LLC raised its position in Madrigal Pharmaceuticals by 490.5% in the first quarter. LPL Financial LLC now owns 30,822 shares of the biopharmaceutical company's stock worth $10,209,000 after purchasing an additional 25,602 shares in the last quarter. Institutional investors own 98.50% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該股票的持倉進行了調整。Envestnet Asset Management Inc.在第一季度將其在 Madrigal Pharmaceuticals 的持股增加了 1.8%。Envestnet Asset Management Inc.目前持有 15,270 股該生物製藥公司的股票，價值為 5,058,000 美元，此前在該期間內又購買了 269 股。安聯資產管理公司在第一季度將其在 Madrigal Pharmaceuticals 的持倉增加了 59.1%。安聯資產管理公司目前持有 1,556 股該生物製藥公司的股票，價值為 515,000 美元，此前在上個季度又收購了 578 股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度購買了 Madrigal Pharmaceuticals 的新股份，價值約為 652,000 美元。Assetmark Inc.在第一季度將其在 Madrigal Pharmaceuticals 的持股增加了 24.0%。Assetmark Inc.目前持有 5,183 股該生物製藥公司的股票，價值為 1,717,000 美元，此前在該期間內又收購了 1,003 股。最後，LPL Financial LLC 在第一季度將其在 Madrigal Pharmaceuticals 的持倉增加了 490.5%。LPL Financial LLC 目前持有 30,822 股該生物製藥公司的股票，價值為 10,209,000 美元，此前在上個季度又購買了 25,602 股。機構投資者持有公司 98.50% 的股票。</p>
</div><h2>About Madrigal Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Madrigal Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於開發用於治療美國非酒精性脂肪性肝炎（NASH）的治療藥物。其主要產品候選藥物是 resmetirom，一種針對肝臟的甲狀腺激素受體β激動劑，目前正在進行 NASH 的三期臨牀試驗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Madrigal Pharmaceuticals</li>
<li>Financial Services Stocks Investing</li>
<li>4 High-Risk Growth Stocks Under $15 to Watch This Fall</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Microsoft’s AI Superfactory Could Power a Stock Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Madrigal Pharmaceuticals</li>
<li>金融服務股票投資</li>
<li>4 只高風險成長股，價格低於 15 美元，值得關注</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>沃爾瑪股票在穩健的第三季度後大幅上漲——未來增長更強勁</li>
<li>尋找並盈利交易 52 周低點的股票</li>
<li>微軟的 AI 超級工廠可能推動股票反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MDGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Madrigal Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Madrigal Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Madrigal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Madrigal Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Madrigal Pharmaceuticals 並不在名單上。</p>
</div><p>While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Madrigal Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Madrigal 製藥（NASDAQ:MDGL）在 HC Wainwright 被設定了新的目標價為 620.00 美元